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Abstract
Introduction: Sertraline and Risperidone are commonly used psychotropic drugs. Sertraline has
previously been associated with eosinopilic pneumonia. Neither drug is recognised as a cause of
diffuse fibrotic lung disease. Our report represents the first such case.
Case Presentation: We describe the case of a 33 year old Asian male with chronic schizophrenia
who had been treated for three years with sertraline and risperidone. He presented to hospital in
respiratory failure following a six month history of progressive breathlessness. High resolution CT
scan demonstrated diffuse pulmonary fibrosis admixed with patchy areas of consolidation. Because
the aetiology of this man's diffuse parenchymal lung disease remained unclear a surgical lung biopsy
was undertaken. Histological assessment disclosed widespread fibrosis with marked eosinophillic
infiltration and associated organising pneumonia - features all highly suggestive of drug induced lung
disease. Following withdrawal of both sertraline and risperidone and initiation of corticosteroid
therapy the patient's respiratory failure resolved and three years later he remains well albeit limited
by breathlessness on heavy exertion.
Conclusion: Drug induced lung disease can be rapidly progressive and if drug exposure continues
may result in respiratory failure and death. Prompt recognition is critical as drug withdrawal may
result in marked resolution of disease. This case highlights sertraline and risperidone as drugs that
may, in susceptible individuals, cause diffuse pulmonary fibrosis.
Introduction
Prescribed medications are an important cause of diffuse
pulmonary fibrosis. Over 300 separate drugs having been
associated with fibrotic lung disease[1]. Because patients
with pulmonary fibrosis frequently present late in the
course of their illness and with advanced disease, a diag-
nosis of drug induced fibrosis is often difficult to confirm.
In many cases of drug induced lung disease the progres-
sion of fibrosis can be halted by withdrawal of the causa-
tive agent. It is crucial therefore that drugs are considered
as a cause of fibrosis especially in cases exhibiting atypical
features.
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The selective seretonin reuptake inhibitor sertraline and
the atypical neuroleptic risperidone are commonly used
psychotropic drugs that are sometimes used in combina-
tion for the treatment of chronic schizophrenia. Sertraline
has been reported in two patients as being the cause of
eosinophilic pneumonia[2,3]. Barnes et al describe a 40
year old lady who had been taking sertraline in combina-
tion with clomipramine and a benzodiazepine for one
week[2]. She presented acutely with diffuse pulmonary
infiltrates and a peripheral blood eosinophillia. Her con-
dition resolved following withdrawal of sertraline. In the
second reported case a 34 year old lady treated with sertra-
line, at an initial dose of 100 mg daily for three months
increasing to 200 mg daily for a further month presented
acutely in respiratory failure. Chest X-ray demonstrated
diffuse alveolar infiltrates and an eosinophillia was found
on bronchoalveolar lavage[3]. A transbronchial biopsy in
this case was consistent with eosinophilic pneumonia.
The patient recovered fully following withdrawal of sertra-
line and treatment with oral corticosteroids.
In this report we describe the case of a 33 year old man
with chronic schizophrenia treated with risperidone and
sertraline who subsequently developed pulmonary fibro-
sis. He presented late in the course of his disease in severe
respiratory failure. Despite this he has subsequently
responded well to withdrawal of his psychotropic medica-
tion. We believe that in this case the clinical history, high
resolution CT findings, surgical lung biopsy and subse-
quent clinical course all strongly support a diagnosis of
sertraline induced pulmonary fibrosis. Neither sertraline
nor risperidone have previously been described in the lit-
erature as a cause of pulmonary fibrosis.
Case Presentation
A 33 year old Asian male with chronic schizophrenia was
admitted to hospital with a six month history of inexora-
bly progressive dyspnoea associated with a dry cough. At
presentation he was in severe respiratory failure (Arterial
blood gas on room air PaO2 7.74 kPa, PaCO2 4.17 kPa).
He had been receiving treatment with risperidone 2 mg
daily and sertraline 50 mg daily for 3 years. He was a cur-
rent tobacco smoker with a five pack year smoking his-
tory. He gave no history of recent travel, illicit substance
abuse or exposure to known pneumotoxic substances.
Physical examination disclosed fine bibasal crackles and
finger clubbing. ESR was elevated at 43 mm/h. Rheuma-
toid factor was 1 in 40. Anti-nuclear antibodies, ANCA,
double stranded DNA antibodies and extractable nuclear
antigens were all negative. High resolution CT demon-
strated diffuse ground glass attenuation with marked retic-
ular change most prominent in the lower lobes (Figure 1).
Also present were multiple discrete areas of consolidation.
Bronchoscopy was unremarkable. Broncho-alveolar lav-
age revealed 26% neutrophils (normal < 7%) and 7.7%
eosinophils (normal < 3%). Bronchial washings were neg-
ative on microscopy and culture for bacteria, fungi and
mycobacteria. Because of uncertainty over the diagnosis a
surgical lung biopsy was undertaken. Left upper and lower
lobe surgical lung biopsies showed a pattern predomi-
nantly of fibrotic non-specific interstitial pneumonia
(NSIP), with coexistent eosinophilic infiltration and occa-
sional foci of organizing pneumonia (Figure 2a and 2b).
The combination of rapid clinical progression, unusual
CT appearances, eosinophilia on broncho-alveolar lavage,
High resolution thoracic CT at time of diagnosis Figure 1
High resolution thoracic CT at time of diagnosis. High resolution CT sections at the level of a) the hila and b) the lung 
bases demonstrate widespread, bilateral ground glass change, multifocal patches of consolidation and evidence of fibrosis with 
fine reticulation and traction bronchiectasis.Journal of Medical Case Reports 2009, 3:126 http://www.jmedicalcasereports.com/content/3/1/126
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biopsy showing prominent eosinophilic infiltration in
association with fibrotic NSIP and an absence of alterna-
tive aetiologies strongly favoured a diagnosis of drug
induced pulmonary fibrosis. Consequently sertraline and
risperidone were stopped. On the advice of the patient's
usual psychiatric team haloperidol was introduced as
replacement anti-psychotic therapy. For the pulmonary
fibrosis, treatment was commenced with intravenous
methylprednisolone 1 g once weekly and cyclophospha-
mide 600 mg/m2 every three weeks for a total of six doses.
This was then converted to low dose oral prednisolone
and azathioprine 150 mg daily with the prednisolone
Photomicrographs of left sided surgical lung biopsy Figure 2
Photomicrographs of left sided surgical lung biopsy. 2a) The lung shows a histological pattern of fibrotic NSIP with dif-
fuse established interstitial fibrosis associated with moderate chronic inflammation (×20 magnification). 2b) The lung at high 
power, shows focal organising pneumonia within a respiratory bronchiole with abundant eosinophils in the adjacent intersti-
tium.
High resolution thoracic CT three years after diagnosis Figure 3
High resolution thoracic CT three years after diagnosis. High resolution CT sections at the level of a) the hilae and b) 
the lung bases demonstrate resolution of the previously noted consolidation and a reduction in ground glass attenuation. How-
ever evidence of fibrosis persists with bilateral reticular change and traction bronchiectasis. The dome of the right hemidia-
phragm is visible in the image of the lung bases (b).Journal of Medical Case Reports 2009, 3:126 http://www.jmedicalcasereports.com/content/3/1/126
Page 4 of 5
(page number not for citation purposes)
slowly being weaned over the succeeding twelve months.
Initial recovery was complicated by the development of a
left sided pneumothorax. However four weeks after with-
drawal of the antipsychotic medication the patient was
ambulatory and no longer in respiratory failure. Three
years on from diagnosis our patient is clinically stable on
treatment with azathioprine alone. HRCT continues to
demonstrate evidence of widespread interstitial fibrosis
but other changes, including the ground glass attenuation
and patchy consolidation, have resolved (Figure 3).
Discussion
Diagnosing drug induced lung disease is always challeng-
ing[1]. Patients with pulmonary fibrosis typically present
at a late stage in their disease making temporal associa-
tions of disease with the commencement of prescribed
medication difficult. Furthermore, as in our case, the
severity of lung damage seen in patients with drug
induced pulmonary fibrosis rarely makes it appropriate to
re-challenge patients with the suspected causative agent.
Clinicians managing suspected drug induced lung disease
are therefore left to exclude other potential causes of fibro-
sis before relying on atypical or ancillary features of a case
to establish a diagnosis.
Potential differential diagnoses for our patient at the time
of his initial presentation included occult connective tis-
sue disease or idiopathic NSIP. The absence of auto-anti-
bodies and the subsequent failure to manifest extra-
thoracic symptoms go strongly against the possibility of
connective tissue disease associated NSIP. The initial CT
appearance and histology and the subsequent clinical
course are not in keeping with a diagnosis of idiopathic
NSIP [4]. We believe that the clinical, histological and
radiological features of this case strongly favour a diagno-
sis of sertraline induced pulmonary fibrosis. This is borne
out by the clinical and radiological response seen follow-
ing drug withdrawal. Areas of consolidation and ground
glass attenuation on CT (areas that likely correspond to
organising pneumonia and eosinophillic inflammation
on biopsy) resolved. Furthermore, pronounced broncho-
alveolar lavage eosinophilia and the marked infiltration
of eosinophils into areas of fibrosis on biopsy are both fre-
quent findings in drug induced lung disease[5]. The sever-
ity of our patient's disease at presentation was such that
we felt it necessary to commence therapy with intravenous
methylprednisolone and cyclophosphamide. It is there-
fore conceivable that his improvement was due to our
therapeutic intervention and unrelated to the discontinu-
ation of his medication. Against this however is the subse-
quent three year stability in this man's disease despite
tapering of corticosteroid and immunosuppressant dos-
ages. Such stability, even following treatment, is unusual
in idiopathic fibrosing lung conditions.
We believe that in our patient's case, sertraline was the
likeliest cause of his fibrosis. Neither sertraline nor risperi-
done have previously been described as causing pulmo-
nary fibrosis. Sertraline however, is a described cause of
eosinophilic pneumonia and furthermore other drugs
within the class of selective serotonin reuptake inhibitors
have been associated with pulmonary fibrosis, granulo-
matous lung disease and hypersensitivity pneumonitis
and acute lung injury [6-8]. Risperidone and the atypical
neuropleptics have not been reported to have pulmonary
side effects. Furthermore, our patient was continued on
haloperidol, a drug that shares many of the pharmacody-
namic features of the atypical neuroleptics including risp-
eridone [9], without this causing further progression of
his respiratory disease. So, although it is impossible to
rule out a role for risperidone in the development of fibro-
sis in our patient, sertraline would seem to be by far the
likeliest causative agent.
In contrast to our case, in the two previously reported
cases of eosinophilic pneumonia occurring in association
with sertraline the affected individuals had only recently
been started on the drug. The duration of our patient's
therapy coupled with the chronicity of his symptoms and
his late presentation may explain why histologically the
fibrotic NSIP appeared to have evolved from a picture
resembling eosinophilic pneumonia. It is interesting to
note that regions of eosinophilic pneumonia, as judged
by HRCT, resolved following discontinuation of sertraline
and risperidone. Established fibrotic NSIP, although not
progressing, did not resolve with therapy or discontinua-
tion of sertraline and risperidone. The pathogenesis of
fibrotic lung diseases including drug induced pulmonary
fibrosis remains poorly understood. In our patient it
seems likely that chronic eosinophilic infiltration has
resulted in persistent airway epithelial injury and through
this process has induced an aberrant, fibrogenic wound
healing response in a manner akin to that postulated to
underlie the pathogenesis of idiopathic pulmonary fibro-
sis[10]. A similar progression of eosinophilic pneumonia
to chronic fibrosis has previously been reported by Yosh-
ida et al in a patient with idiopathic disease[11]. A further
possible precipitant for our patient progressing to fibrosis
is the fact that he was a smoker. Smoking appears to be a
potential co-factor in the development of a number of
fibrotic lung conditions[12].
Conclusion
This case highlights the need for physicians to be alert to
the possibility that sertraline and possibly risperidone
may be a potential cause of eosinophilic pneumonia and
progressive pulmonary fibrosis. It is important that drugs
are recognized as a cause of fibrotic lung disease because,
as in the case presented in this report, prompt early treat-Publish with BioMed Central    and   every 
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ment and drug cessation can arrest disease progression
and lead to a marked improvement in respiratory func-
tion.
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